Vaxess Announces Production of The First GMP Batch of MIMIX™ Technology Vaccine Patches for an Upcoming Phase 1 Seasonal Influenza Clinical Trial
April 5th, 2022 | 🕒
Powered by iSpeech CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vaxess Technologies, Inc., an innovative life sciences company developing a pipeline of shelf-stable and
Gloss